ProCE Banner Activity

Cancer Conversations™:
Improving Outcomes With Immunotherapy and Targeted Agents in RCC

Slideset Download
Download these slides from a live webinar for the most recent data on selecting the optimal treatment options for patients with advanced RCC.

Released: November 01, 2021

Expiration: October 31, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Eisai

Exelixis, Inc.

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Rana R. McKay, MD

Professor of Medicine and Urology
Moores Cancer Center
University of California San Diego
La Jolla, California

Rana R. McKay, MD, has disclosed that she has received funds for research support from Bayer and Pfizer and consulting fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Calithera, Dendreon, Exelixis, Johnson & Johnson, Merck, Novartis, and Pfizer.

Elizabeth Plimack, MD, MS

Assistant Professor
Associate Member
Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Elizabeth R. Plimack, MD, MS, has disclosed that she has received funds for research support from AstraZeneca, Bristol-Myers Squibb, Genentech, and Merck and consulting fees from AstraZeneca, Bristol-Myers Squibb, Calithera, Flatiron, Genentech, Infinity, Janssen, MEI, Merck, Pfizer, and Seattle Genetics.

Brian I. Rini, MD

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio

Brian Rini, MD, FASCO, has disclosed that he has received funds for research support from Aravive, Arrowhead, AVEO, Bristol-Myers Squibb, Eisai, Merck, and Pfizer; consulting fees from Aravive, Arrowhead, AVEO, Bristol-Myers Squibb, Eisai, Merck, Nikang, and Pfizer; and other financial or material support from Merck and Pfizer.